A study from China reported 12.3% of T2D-CKD patients were on SGLT2 inhibitors, while another study found that only 11.9% of American diabetes patients who met clinical criteria for SGLT2i therapy were prescribed the medication.6,7. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.